Findings

What do systematic reviews say?

4 questions · 4 findings · 4 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

Platinum‐containing chemotherapy vs chemotherapy without platinum

Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer

Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
RR 1.16 [0.89, 1.49]
12 studies · 3771 participants
Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Febrile neutropenia · women with early breast cancer

Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
OR 1.43 [0.89, 2.31]
23 studies · 34154 participants
Moderate

Intervention not reported

Febrile neutropenia Rates of patients · breast cancer patients undergoing chemotherapy

The intervention probably leads to lower febrile neutropenia Rates of patients (moderate certainty).

1 finding from 1 review

Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in… 2012 · Cochrane Headline outcomes only
RR 0.27 [0.11, 0.7]
6 studies · 2073 participants
Moderate

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Febrile neutropenia · patients with early breast cancer

Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
OR 0.55 [0.47, 0.64]
5 studies · 8086 participants
Moderate